• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Natural processing sites for human cathepsin E and cathepsin D in tetanus toxin: implications for T cell epitope generation.

作者信息

Hewitt E W, Treumann A, Morrice N, Tatnell P J, Kay J, Watts C

机构信息

Department of Biochemistry, Medical Sciences Institute, University of Dundee, United Kingdom.

出版信息

J Immunol. 1997 Nov 15;159(10):4693-9.

PMID:9366392
Abstract

Cathepsin E is an aspartic proteinase that has been implicated frequently in Ag processing for presentation on class II MHC molecules, but no information exists on its cleavage specificity within Ags in relation to known T cell epitopes. We have analyzed the processing by cathepsin E of a large C-terminal domain of tetanus toxin (residues 872-1315), and we have compared the processing products with those liberated by cathepsin D, a related aspartic proteinase also thought to be involved in class II MHC-restricted Ag processing. Processing products were analyzed by N-terminal Edman degradation and mass spectrometry following reverse-phase HPLC separation of peptides. A total of 28 cleavage sites was identified, 11 of which were recognized by both cathepsins E and D. Most, although not all, sites were between pairs of hydrophobic residues and were located within the 200-amino-acid C terminal region known to contain several human T cell epitopes. Previously described T cell epitopes, for example, between residues 1273 and 1284, were flanked by cathepsin E and D cleavage sites. These data are consistent with an important role for cathepsins E and/or D in Ag processing in the human immune system.

摘要

相似文献

1
Natural processing sites for human cathepsin E and cathepsin D in tetanus toxin: implications for T cell epitope generation.
J Immunol. 1997 Nov 15;159(10):4693-9.
2
Cathepsin D, but not cathepsin B, releases T cell stimulatory fragments from lysozyme that are functional in the context of multiple murine class II MHC molecules.组织蛋白酶D而非组织蛋白酶B可从溶菌酶中释放出对多种小鼠II类主要组织相容性复合体分子起作用的T细胞刺激片段。
Eur J Immunol. 1994 Sep;24(9):2175-80. doi: 10.1002/eji.1830240936.
3
Potential sites for processing of the human invariant chain by cathepsins D and E.组织蛋白酶D和E处理人恒定链的潜在位点。
Biochem Biophys Res Commun. 1996 Jun 25;223(3):549-53. doi: 10.1006/bbrc.1996.0932.
4
Modulation of antigen processing and presentation by covalently linked complement C3b fragment.通过共价连接的补体C3b片段对抗原加工和呈递的调节
Immunology. 1995 Jan;84(1):164-70.
5
Destructive potential of the aspartyl protease cathepsin D in MHC class II-restricted antigen processing.天冬氨酸蛋白酶组织蛋白酶D在MHC II类限制性抗原加工中的破坏潜力。
Eur J Immunol. 2005 Dec;35(12):3442-51. doi: 10.1002/eji.200535320.
6
Antigen processing by endosomal proteases determines which sites of sperm-whale myoglobin are eventually recognized by T cells.内体蛋白酶对抗原的加工决定了抹香鲸肌红蛋白的哪些位点最终会被T细胞识别。
Eur J Immunol. 1991 Sep;21(9):1989-96. doi: 10.1002/eji.1830210904.
7
Processing of tetanus toxin by human antigen-presenting cells. Evidence for donor and epitope-specific processing pathways.人抗原呈递细胞对破伤风毒素的加工处理。供体和表位特异性加工途径的证据。
J Immunol. 1989 Dec 15;143(12):3881-6.
8
Cathepsin E regulates the presentation of tetanus toxin C-fragment in PMA activated primary human B cells.组织蛋白酶E调节佛波酯激活的原代人B细胞中破伤风毒素C片段的呈递。
Biochem Biophys Res Commun. 2008 Dec 26;377(4):1299-303. doi: 10.1016/j.bbrc.2008.10.162. Epub 2008 Nov 6.
9
Epitope repertoire of human CD4+ lines propagated with tetanus toxoid or with synthetic tetanus toxin sequences.用破伤风类毒素或合成破伤风毒素序列增殖的人CD4 +细胞系的表位库。
J Autoimmun. 1996 Feb;9(1):79-88. doi: 10.1006/jaut.1996.0010.
10
Delineation of several DR-restricted tetanus toxin T cell epitopes.几种DR限制的破伤风毒素T细胞表位的描绘。
J Immunol. 1989 Jan 15;142(2):394-402.

引用本文的文献

1
Ensilicated tetanus antigen retains immunogenicity: in vivo study and time-resolved SAXS characterization.硅酸化破伤风抗原保持免疫原性:体内研究和时间分辨 SAXS 表征。
Sci Rep. 2020 Jun 8;10(1):9243. doi: 10.1038/s41598-020-65876-3.
2
Orchestration of Adaptive T Cell Responses by Neutrophil Granule Contents.中性粒细胞颗粒内容物对适应性 T 细胞应答的调控。
Mediators Inflamm. 2019 Mar 10;2019:8968943. doi: 10.1155/2019/8968943. eCollection 2019.
3
A novel C3d-containing oligomeric vaccine provides insight into the viability of testing human C3d-based vaccines in mice.
一种新型含C3d的寡聚疫苗为在小鼠中测试基于人C3d的疫苗的可行性提供了见解。
Immunobiology. 2018 Jan;223(1):125-134. doi: 10.1016/j.imbio.2017.10.002. Epub 2017 Oct 4.
4
Thermal stability, storage and release of proteins with tailored fit in silica.在二氧化硅中具有定制契合度的蛋白质的热稳定性、储存和释放。
Sci Rep. 2017 Apr 24;7:46568. doi: 10.1038/srep46568.
5
The signal peptide of the tumor-shared antigen midkine hosts CD4+ T cell epitopes.肿瘤共享抗原中期因子的信号肽含有 CD4+T 细胞表位。
J Biol Chem. 2013 May 10;288(19):13370-7. doi: 10.1074/jbc.M112.427302. Epub 2013 Apr 3.
6
Synthetic neoglycoconjugates of cell-surface phosphoglycans of Leishmania as potential anti-parasite carbohydrate vaccines.合成的利什曼原虫细胞表面磷酸糖的糖缀合物作为潜在的抗寄生虫碳水化合物疫苗。
Biochemistry (Mosc). 2011 Jul;76(7):761-73. doi: 10.1134/S0006297911070066.
7
Implication of granulocyte-macrophage colony-stimulating factor induced neutrophil gelatinase-associated lipocalin in pathogenesis of rheumatoid arthritis revealed by proteome analysis.通过蛋白质组分析揭示粒细胞-巨噬细胞集落刺激因子诱导的中性粒细胞明胶酶相关脂质运载蛋白在类风湿关节炎发病机制中的意义。
Arthritis Res Ther. 2009;11(1):R3. doi: 10.1186/ar2587.
8
Cathepsin G: roles in antigen presentation and beyond.组织蛋白酶 G:在抗原呈递中的作用及其他作用。
Mol Immunol. 2010 Jan;47(4):658-65. doi: 10.1016/j.molimm.2009.10.003. Epub 2009 Nov 11.
9
Reconstruction of a pathway of antigen processing and class II MHC peptide capture.抗原加工途径及II类主要组织相容性复合体肽捕获的重建
EMBO J. 2007 Apr 18;26(8):2137-47. doi: 10.1038/sj.emboj.7601660. Epub 2007 Mar 29.
10
Cathepsin D is up-regulated in inflammatory bowel disease macrophages.组织蛋白酶D在炎症性肠病巨噬细胞中上调。
Clin Exp Immunol. 2004 Apr;136(1):157-67. doi: 10.1111/j.1365-2249.2004.02420.x.